药效团
虚拟筛选
化学
IC50型
赫拉
对接(动物)
立体化学
CDC25A型
铅化合物
组合化学
蒂奥-
计算生物学
生物化学
生物
体外
细胞周期
细胞
细胞周期检查点
护理部
医学
作者
Yushu Ge,Qianqian Han,Wenxiu Duan,Jia‐Qi Zhang,Kai Chen,Jia‐Jia Wan,Yi Liu,Dan Liu
出处
期刊:ChemMedChem
[Wiley]
日期:2017-02-15
卷期号:12 (6): 438-447
被引量:4
标识
DOI:10.1002/cmdc.201600644
摘要
Abstract Cdc25 phosphatase was studied as an attractive target for cancer therapy. Multiple pharmacophore models with the unique core features of classic quinone inhibitors and those of novel inhibitors were used to discover a novel lead inhibitor. A total of 21 compounds with qualified physical properties were screened from the Maybridge HitFinder database containing 14 400 compounds by pharmacophore models. Four compounds were found to inhibit Cdc25A activity by more than 50 % at a concentration of 100 μ m . Among these compounds, KM10389 ( N ‐{2‐[(furan‐2‐ylmethyl)thio]ethyl}‐2‐[(4‐hydroxy‐6‐propylpyrimidin‐2‐yl)thio]acetamide) showed high inhibitory activity with an IC 50 value of 7.9 μ m . Selective cytotoxicity toward HeLa cells was observed with an IC 50 value of 66.3 μ m , whereas the IC 50 value for HEK293 cells was higher than 100 μ m . Blocking of the G1/S transition was also observed for HeLa cells in the presence of the compound by increasing the G1 phase by 16.15 %. Together with compounds HTS02435 and HTS01205, a novel lead inhibitor structure was identified and analyzed by a molecular docking study. The implication of virtual screening by using different pharmacophore models representing the different features is fully discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI